148 related articles for article (PubMed ID: 29341586)
1. Development of a Cytopathic Effect-Based Phenotypic Screening Assay against Cryptosporidium.
Chao AT; Lee BH; Wan KF; Selva J; Zou B; Gedeck P; Beer DJ; Diagana TT; Bonamy GMC; Manjunatha UH
ACS Infect Dis; 2018 Apr; 4(4):635-645. PubMed ID: 29341586
[TBL] [Abstract][Full Text] [Related]
2. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
[TBL] [Abstract][Full Text] [Related]
3. Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth
Funkhouser-Jones LJ; Ravindran S; Sibley LD
mBio; 2020 Mar; 11(2):. PubMed ID: 32127445
[No Abstract] [Full Text] [Related]
4. Evaluation of putative anti-cryptosporidial drugs in an in vitro culture system.
Schupfner M; Greif G; Lendner M; Daugschies A; Lippuner C; von Samson-Himmelstjerna G; Krücken J
Parasitol Res; 2013 Aug; 112 Suppl 1():149-62. PubMed ID: 23765343
[TBL] [Abstract][Full Text] [Related]
5. High-Content Screening for Cryptosporidium Drug Discovery.
Love MS; McNamara CW
Methods Mol Biol; 2020; 2052():303-317. PubMed ID: 31452169
[TBL] [Abstract][Full Text] [Related]
6. Cryptosporidium and Toxoplasma Parasites Are Inhibited by a Benzoxaborole Targeting Leucyl-tRNA Synthetase.
Palencia A; Liu RJ; Lukarska M; Gut J; Bougdour A; Touquet B; Wang ED; Li X; Alley MR; Freund YR; Rosenthal PJ; Hakimi MA; Cusack S
Antimicrob Agents Chemother; 2016 Oct; 60(10):5817-27. PubMed ID: 27431220
[TBL] [Abstract][Full Text] [Related]
7. A screening pipeline for antiparasitic agents targeting cryptosporidium inosine monophosphate dehydrogenase.
Sharling L; Liu X; Gollapalli DR; Maurya SK; Hedstrom L; Striepen B
PLoS Negl Trop Dis; 2010 Aug; 4(8):e794. PubMed ID: 20706578
[TBL] [Abstract][Full Text] [Related]
8. Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box.
Bessoff K; Spangenberg T; Foderaro JE; Jumani RS; Ward GE; Huston CD
Antimicrob Agents Chemother; 2014 May; 58(5):2731-9. PubMed ID: 24566188
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.
Bessoff K; Sateriale A; Lee KK; Huston CD
Antimicrob Agents Chemother; 2013 Apr; 57(4):1804-14. PubMed ID: 23380723
[TBL] [Abstract][Full Text] [Related]
10. Cryptosporidiosis Drug Discovery: Opportunities and Challenges.
Manjunatha UH; Chao AT; Leong FJ; Diagana TT
ACS Infect Dis; 2016 Aug; 2(8):530-7. PubMed ID: 27626293
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Screening of Drugs Against the Growth of Cryptosporidium parvum In Vitro by qRT-PCR.
Zhang H; Zhu G
Methods Mol Biol; 2020; 2052():319-334. PubMed ID: 31452170
[TBL] [Abstract][Full Text] [Related]
12. Novel lactate dehydrogenase inhibitors with in vivo efficacy against Cryptosporidium parvum.
Li K; Nader SM; Zhang X; Ray BC; Kim CY; Das A; Witola WH
PLoS Pathog; 2019 Jul; 15(7):e1007953. PubMed ID: 31356619
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-Cryptosporidium activity of known drugs identified by high-throughput screening against parasite fatty acyl-CoA binding protein (ACBP).
Fritzler JM; Zhu G
J Antimicrob Chemother; 2012 Mar; 67(3):609-17. PubMed ID: 22167242
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic screening techniques for
Love MS; McNamara CW
Expert Opin Drug Discov; 2021 Jan; 16(1):59-74. PubMed ID: 32892652
[No Abstract] [Full Text] [Related]
16. A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.
Ndao M; Nath-Chowdhury M; Sajid M; Marcus V; Mashiyama ST; Sakanari J; Chow E; Mackey Z; Land KM; Jacobson MP; Kalyanaraman C; McKerrow JH; Arrowood MJ; Caffrey CR
Antimicrob Agents Chemother; 2013 Dec; 57(12):6063-73. PubMed ID: 24060869
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model.
Downey AS; Chong CR; Graczyk TK; Sullivan DJ
Antimicrob Agents Chemother; 2008 Sep; 52(9):3106-12. PubMed ID: 18591280
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
[TBL] [Abstract][Full Text] [Related]
19. 5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.
Huang W; Choi R; Hulverson MA; Zhang Z; McCloskey MC; Schaefer DA; Whitman GR; Barrett LK; Vidadala RSR; Riggs MW; Maly DJ; Van Voorhis WC; Ojo KK; Fan E
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533246
[No Abstract] [Full Text] [Related]
20. Efficacy of nitazoxanide, tizoxanide and tizoxanide glucuronide against Cryptosporidium parvum development in sporozoite-infected HCT-8 enterocytic cells.
Gargala G; Delaunay A; Li X; Brasseur P; Favennec L; Ballet JJ
J Antimicrob Chemother; 2000 Jul; 46(1):57-60. PubMed ID: 10882689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
